In stroke models, GLP-1RA therapy mitigates astrocyte-derived damage: experimental data show GLP-1R agonists reduce astrocytic release of MMP-9, IL-1, and IL-6 that otherwise disrupt the blood–brain barrier [103]. Here, IL1B is linked to stroke disorder.